Clinical Trial Update: A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies [Phase 1]

View source ↗

Summary

A Phase I trial of OSI-906 in combination with pemetrexed for advanced solid tumor malignancies has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Alimta (pemetrexed)
• OSI-906 (OSI-906)

Snippet

Sponsor: Emory University | Conditions: Cancer, Neoplasms | Phase 1 | Status: WITHDRAWN